Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Chubb
UBS
Cipla
Argus Health
Chinese Patent Office
Merck
Cerilliant

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,715,710

« Back to Dashboard

Which drugs does patent 8,715,710 protect, and when does it expire?

Patent 8,715,710 protects SUSTOL and is included in one NDA.

This patent has sixteen patent family members in ten countries.
Summary for Patent: 8,715,710
Title:Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s): Ng; Steven Y. (San Francisco, CA), Shen; Hui Rong (Fremont, CA), Heller; Jorge (Ashland, OR)
Assignee: Heron Therapeutics, Inc. (Redwood City, CA)
Application Number:13/552,083
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,715,710

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Heron Theraps Inc SUSTOL granisetron INJECTION, EXTENDED RELEASE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,715,710

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,861,068 Pharmaceutical compositions using semi-solid delivery vehicle ➤ Try a Free Trial
8,252,304 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron ➤ Try a Free Trial
8,252,305 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron ➤ Try a Free Trial
6,613,355 Semi-solid delivery vehicle and pharmaceutical compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,715,710

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005289425 ➤ Try a Free Trial
Canada 2579297 ➤ Try a Free Trial
China 101052376 ➤ Try a Free Trial
European Patent Office 1796629 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Cantor Fitzgerald
Harvard Business School
Moodys
Queensland Health
Merck
McKesson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.